163 related articles for article (PubMed ID: 30713500)
1. Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver.
Hentilä J; Nissinen TA; Korkmaz A; Lensu S; Silvennoinen M; Pasternack A; Ritvos O; Atalay M; Hulmi JJ
Front Physiol; 2018; 9():1917. PubMed ID: 30713500
[TBL] [Abstract][Full Text] [Related]
2. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.
Hulmi JJ; Hentilä J; DeRuisseau KC; Oliveira BM; Papaioannou KG; Autio R; Kujala UM; Ritvos O; Kainulainen H; Korkmaz A; Atalay M
Free Radic Biol Med; 2016 Oct; 99():308-322. PubMed ID: 27554968
[TBL] [Abstract][Full Text] [Related]
3. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
4. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
5. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
[TBL] [Abstract][Full Text] [Related]
6. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.
Nissinen TA; Degerman J; Räsänen M; Poikonen AR; Koskinen S; Mervaala E; Pasternack A; Ritvos O; Kivelä R; Hulmi JJ
Sci Rep; 2016 Sep; 6():32695. PubMed ID: 27666826
[TBL] [Abstract][Full Text] [Related]
7. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
8. Muscle NAD
Hulmi JJ; Penna F; Pöllänen N; Nissinen TA; Hentilä J; Euro L; Lautaoja JH; Ballarò R; Soliymani R; Baumann M; Ritvos O; Pirinen E; Lalowski M
Mol Metab; 2020 Nov; 41():101046. PubMed ID: 32599075
[TBL] [Abstract][Full Text] [Related]
9. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
10. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of activin receptor 2 signalling ameliorates metabolic dysfunction-associated steatotic liver disease in western diet/L-NAME induced cardiometabolic disease.
Swan J; Szabó Z; Peters J; Kummu O; Kemppi A; Rahtu-Korpela L; Konzack A; Hakkola J; Pasternack A; Ritvos O; Kerkelä R; Magga J
Biomed Pharmacother; 2024 Jun; 175():116683. PubMed ID: 38705130
[TBL] [Abstract][Full Text] [Related]
12. Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function.
Szabó Z; Vainio L; Lin R; Swan J; Hulmi JJ; Rahtu-Korpela L; Serpi R; Laitinen M; Pasternack A; Ritvos O; Kerkelä R; Magga J
FASEB J; 2020 Aug; 34(8):9911-9924. PubMed ID: 32427381
[TBL] [Abstract][Full Text] [Related]
13. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
14. The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.
Bohnert KR; Goli P; Roy A; Sharma AK; Xiong G; Gallot YS; Kumar A
Mol Cell Biol; 2019 Aug; 39(15):. PubMed ID: 31138662
[TBL] [Abstract][Full Text] [Related]
15. Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia.
O'Connell TM; Pin F; Couch ME; Bonetto A
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31438622
[TBL] [Abstract][Full Text] [Related]
16. Muscle PGC-1α in exercise and fasting-induced regulation of hepatic UPR in mice.
Kristensen CM; Jessen H; Ringholm S; Pilegaard H
Acta Physiol (Oxf); 2018 Dec; 224(4):e13158. PubMed ID: 29939478
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum stress and unfolded protein response profile in quadriceps of sarcopenic patients with respiratory diseases.
Barreiro E; Salazar-Degracia A; Sancho-Muñoz A; Gea J
J Cell Physiol; 2019 Jul; 234(7):11315-11329. PubMed ID: 30565689
[TBL] [Abstract][Full Text] [Related]
18. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
[TBL] [Abstract][Full Text] [Related]
19. Moderate Exercise Improves Experimental Cancer Cachexia by Modulating the Redox Homeostasis.
Ballarò R; Penna F; Pin F; Gómez-Cabrera MC; Viña J; Costelli P
Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30823492
[TBL] [Abstract][Full Text] [Related]
20. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
